Combination Therapy in Treatment of Experimental Ischemic Heart Disease – A Preclinical Study | Chapter 13 | Trends in Pharmaceutical Research and Development Vol. 1

Combination Therapy in Treatment of Experimental Ischemic Heart Disease – A Preclinical Study | Chapter 13 | Trends in Pharmaceutical Research and Development Vol. 1

The present study was designed to investigate the role of combined administration of Ramipril and Candesartan against in vitro myocardial ischemic reperfusion injury in rat. Male Wistar albino rats were divided into five groups (= 6) and treated with saline (10 mL/kg), Ramipril (2 mg/kg), Candesartan (1 mg/kg), and the combination of both drugs, respectively 24 h before induction of global ischemia (5 min of stabilization, 9 min of global ischemia and 12 min of reflow). Combination of Ramipril and Candesartan when compared to the monotherapy significantly increased the levels of superoxide dismutase, reduced glutathione, catalase and nitric oxide and decreased the levels of thiobarbituric acid reactive substances. In addition, the superior protective role of combination of Ramipril and Candesartan on ischemia induced myocardial damage was further confirmed by well preserved myocardial tissue architecture in light microscopy and transmission electron microscopy analysis studies. The combination was proved to be effective in salvaging the myocardial tissue against ischemic reperfusion injury when compared to the monotherapy of individual drugs and further investigations on protective mechanism of drugs by increasing the nitric oxide level at molecular levels are needed.

Author (s) Details

Dr. Mohamed Saleem Thattakudian Sheikuduman
Department of Pharmacology, College of Pharmacy, Riyadh ELM University, P.O.Box 84891 Riyadh 11681, Kingdom of Saudi Arabia and Annamacharya College of Pharmacy, Rajampet-516126, Andhra Pradesh, India

View Book :- http://bp.bookpi.org/index.php/bpi/catalog/book/156

Editor 251News

leave a comment

Create Account



Log In Your Account